Together, we demonstrated that MYC overexpression modified the cellular response to trametinib by enhancing the DNA damage response, as evidenced by the increased γH2A.X levels, while also partially mitigating transcriptional inhibition in HNSCC cells. Here, MYC is linked to head and neck squamous cell carcinoma.